Search research articles
Contact Us
Filters
Showing results (61-70 of 106) with videos related to
Page
of 11
Sort By:
Journal of the American College of Cardiology
|
March 27, 2010
Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study
Lisbeth Bonde, Rikke Sorensen, Emil Loldrup Fosbøl, et al.
European Heart Journal
|
February 15, 2011
Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction
Scott D Solomon, Sung Hee Shin, Amil Shah, et al.
American Heart Journal
|
February 23, 2021
Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials
Muhammad Shahzeb Khan, Soren Lund Kristensen, Muthiah Vaduganathan, et al.
JACC. Cardiovascular Imaging
|
April 10, 2009
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
Anil Verma, Alessandra Meris, Hicham Skali, et al.
Hypertension (Dallas, Tex. : 1979)
|
November 21, 2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction
Jens J Thune, James Signorovitch, Lars Kober, et al.
European Journal of Heart Failure
|
July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial
Safia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
Cardiovascular Research
|
November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction
Shingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.
JACC. Heart Failure
|
April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)
Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
American Heart Journal
|
August 23, 2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Shelby D Reed, John J V McMurray, Eric J Velazquez, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
October 9, 2021
Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017
Anojhaan Arulmurugananthavadivel, Anders Holt, Saaima Parveen, et al.
Page
of 11
Search research articles
Search
Showing results (61-70 of 106) with videos related to
Sort By:
Page
of 11
Journal of the American College of Cardiology
|
March 27, 2010
Increased mortality associated with low use of clopidogrel in patients with heart failure and acute myocardial infarction not undergoing percutaneous coronary intervention: a nationwide study
Lisbeth Bonde, Rikke Sorensen, Emil Loldrup Fosbøl, et al.
European Heart Journal
|
February 15, 2011
Effect of the direct renin inhibitor aliskiren on left ventricular remodelling following myocardial infarction with systolic dysfunction
Scott D Solomon, Sung Hee Shin, Amil Shah, et al.
American Heart Journal
|
February 23, 2021
Natriuretic peptide plasma concentrations and risk of cardiovascular versus non-cardiovascular events in heart failure with reduced ejection fraction: Insights from the PARADIGM-HF and ATMOSPHERE trials
Muhammad Shahzeb Khan, Soren Lund Kristensen, Muthiah Vaduganathan, et al.
JACC. Cardiovascular Imaging
|
April 10, 2009
Prognostic implications of left ventricular mass and geometry following myocardial infarction: the VALIANT (VALsartan In Acute myocardial iNfarcTion) Echocardiographic Study
Anil Verma, Alessandra Meris, Hicham Skali, et al.
Hypertension (Dallas, Tex. : 1979)
|
November 21, 2007
Effect of antecedent hypertension and follow-up blood pressure on outcomes after high-risk myocardial infarction
Jens J Thune, James Signorovitch, Lars Kober, et al.
European Journal of Heart Failure
|
July 27, 2022
Longitudinal trajectories in renal function before and after heart failure hospitalization among patients with heart failure with preserved ejection fraction in the PARAGON-HF trial
Safia Chatur, Muthiah Vaduganathan, Alexander Peikert, et al.
Cardiovascular Research
|
November 17, 2025
Obesity, aldosterone, and natriuretic peptide in patients with heart failure and reduced ejection fraction
Shingo Matsumoto, Jawad H Butt, Kieran F Docherty, et al.
JACC. Heart Failure
|
April 12, 2014
Impact of cardiovascular events on change in quality of life and utilities in patients after myocardial infarction: a VALIANT study (valsartan in acute myocardial infarction)
Eldrin F Lewis, Yanhong Li, Marc A Pfeffer, et al.
American Heart Journal
|
August 23, 2006
Geographic variation in the treatment of acute myocardial infarction in the VALsartan In Acute myocardial iNfarcTion (VALIANT) trial
Shelby D Reed, John J V McMurray, Eric J Velazquez, et al.
European Heart Journal. Quality of Care & Clinical Outcomes
|
October 9, 2021
Importance of diagnostic setting in determining mortality in patients with new-onset heart failure: temporal trends in Denmark from 1997 to 2017
Anojhaan Arulmurugananthavadivel, Anders Holt, Saaima Parveen, et al.
Page
of 11